Thermo Fisher Scientific Inc. has unveiled the Thermo Scientific Cellomics Micronucleus v3.0 BioApplication—a new solution that uses a cell-based approach for a comprehensive assessment of genotoxicity. The Micronucleus BioApplication relies on the Thermo Scientific Cellomics ArrayScan VTI system, which comprises high-content screening instrumentation, informatics and reagent products, allowing researchers to more rapidly test multiple compounds to discover potential toxic effects on genetic material. This application provides a more reproducible method for compound screening at substantially lower labor costs than traditional manual approaches to micronuclei quantification.
This article was published in Drug Discovery & Development magazine: Vol. 11, No. 5, May, 2008, pp. 41.
Filed Under: Genomics/Proteomics
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)
